These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15068500)

  • 101. Efficacy of raloxifene for treatment of menopause: a systematic review.
    Boyack M; Lookinland S; Chasson S
    J Am Acad Nurse Pract; 2002 Apr; 14(4):150-65. PubMed ID: 12001746
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia.
    Mosca L; Harper K; Sarkar S; O'Gorman J; Anderson PW; Cox DA; Barrett-Connor E
    Clin Ther; 2001 Sep; 23(9):1552-65. PubMed ID: 11589267
    [TBL] [Abstract][Full Text] [Related]  

  • 103. A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density.
    Detilleux J; Reginster JY; Chines A; Bruyère O
    Stat Methods Med Res; 2016 Feb; 25(1):400-12. PubMed ID: 22967963
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Effects of the selective oestrogen receptor modulator-raloxifene-on calcium and PTH secretory dynamics in women with osteoporosis.
    Oleksik A; Duong T; Popp-Snijders C; Pliester N; Asma G; Lips P
    Clin Endocrinol (Oxf); 2001 May; 54(5):575-82. PubMed ID: 11380487
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures.
    Oleksik AM; Ewing S; Shen W; van Schoor NM; Lips P
    Osteoporos Int; 2005 Aug; 16(8):861-70. PubMed ID: 15558238
    [TBL] [Abstract][Full Text] [Related]  

  • 106. How does raloxifene reduce fracture risk?
    McClung MR
    Menopause; 2002; 9(5):306-8. PubMed ID: 12218718
    [No Abstract]   [Full Text] [Related]  

  • 107. Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04.
    Uemura Y; Tanaka S; Miyazaki T; Tsukiyama M; Sone T; Taguchi A; Soen S; Mori S; Hagino H; Sugimoto T; Fukunaga M; Ohta H; Nakamura T; Orimo H; Shiraki M;
    J Bone Miner Metab; 2019 May; 37(3):491-495. PubMed ID: 30019249
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Postmenopausal osteoporosis management.
    Gambacciani M; Ciaponi M
    Curr Opin Obstet Gynecol; 2000 Jun; 12(3):189-97. PubMed ID: 10873119
    [TBL] [Abstract][Full Text] [Related]  

  • 109. [Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis].
    Štěpán J; Rosa J; Pavelka K
    Vnitr Lek; 2016; 62(10):781-788. PubMed ID: 27900864
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study.
    Burge R; Shen W; Naegeli AN; Alam J; Silverman S; Gold DT; Shih T
    Health Qual Life Outcomes; 2013 Nov; 11():189. PubMed ID: 24192207
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis.
    Nakamura T; Liu JL; Morii H; Huang QR; Zhu HM; Qu Y; Hamaya E; Thiebaud D
    J Bone Miner Metab; 2006; 24(5):414-8. PubMed ID: 16937275
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Assessment of protein oxidation in women using raloxifene.
    Korucuoğlu U; Ciftçi B; Gülbahar O; Biri A; Nas T; Gürsoy R; Aricioğlu A
    Mol Cell Biochem; 2006 Oct; 290(1-2):97-101. PubMed ID: 16941230
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus.
    Kanazawa I; Yamaguchi T; Yamamoto M; Yamauchi M; Yano S; Sugimoto T
    Osteoporos Int; 2007 Dec; 18(12):1675-81. PubMed ID: 17632742
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Raloxifene in the Treatment of Osteoporosis in Postmenopausal Women with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
    Ma HY; Chen S; Lu LL; Gong W; Zhang AH
    Horm Metab Res; 2021 Nov; 53(11):730-737. PubMed ID: 34740274
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy.
    Carr MC; Knopp RH; Brunzell JD; Wheeler BS; Zhu X; Lakshmanan M; Rosen AS; Anderson PW
    Diabetes Care; 2005 Jul; 28(7):1555-61. PubMed ID: 15983300
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study.
    Shen W; Burge R; Naegeli AN; Shih J; Alam J; Gold DT; Silverman S
    BMC Musculoskelet Disord; 2014 Nov; 15():374. PubMed ID: 25403238
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Relationships between dimethylarginine and the presence of vertebral fractures in type 2 diabetes mellitus.
    Kanazawa I; Yano S; Yamaguchi T; Notsu Y; Nabika T; Sugimoto T
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):463-8. PubMed ID: 20550537
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Medication update.
    Slagle MA
    South Med J; 2001 Jun; 94(6):574-8. PubMed ID: 11440325
    [No Abstract]   [Full Text] [Related]  

  • 119. The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers.
    Umland EM; Rinaldi C; Parks SM; Boyce EG
    Ann Pharmacother; 1999 Dec; 33(12):1315-28. PubMed ID: 10630832
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance.
    Iikuni N; Hamaya E; Nihojima S; Yokoyama S; Goto W; Taketsuna M; Miyauchi A; Sowa H
    J Bone Miner Metab; 2012 Nov; 30(6):674-82. PubMed ID: 22752125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.